Figure 2
VAG539 treatment induces antigen-specific unresponsiveness. VAG539- or saline-treated Balb/c mice (n = 3) were immunized with OVA in CFA. (A) Draining lymph node cells were analyzed 7 days after immunization for expression of CD80 and CD86 by CD11c+ DCs (2-tailed t test: *P < .05). (B) Seven days after immunization, draining lymph node cells were stimulated with irradiated C57Bl/6 CD90− antigen-presenting cells (1:1 ratio; proliferation of stimulator cells alone was < 200 cpm), with Con A (1.25 μg/mL) or with OVA at the indicated concentrations. After 3 days of culture, 1 μCi (0.037 MBq)/well 3H-thymidine was added for additional 16 hours (2-tailed t tests: *P < .05). Error bars represent standard deviation between different mice (n = 3).

VAG539 treatment induces antigen-specific unresponsiveness. VAG539- or saline-treated Balb/c mice (n = 3) were immunized with OVA in CFA. (A) Draining lymph node cells were analyzed 7 days after immunization for expression of CD80 and CD86 by CD11c+ DCs (2-tailed t test: *P < .05). (B) Seven days after immunization, draining lymph node cells were stimulated with irradiated C57Bl/6 CD90 antigen-presenting cells (1:1 ratio; proliferation of stimulator cells alone was < 200 cpm), with Con A (1.25 μg/mL) or with OVA at the indicated concentrations. After 3 days of culture, 1 μCi (0.037 MBq)/well 3H-thymidine was added for additional 16 hours (2-tailed t tests: *P < .05). Error bars represent standard deviation between different mice (n = 3).

Close Modal

or Create an Account

Close Modal
Close Modal